Xlife Sciences AG (id:13147 XLS)
28.90 CHF
Opening hours: 09:00 - 17:20 (Central European Standard Time: 11/22/2024 2:59:22 AM)
Exchange closed, opens in 6 hours
About Xlife Sciences AG
Market Capitalization 164.21M
Xlife Sciences AG focuses on the development and commercialization of technologies in the life sciences sector. The company's project consists of technology platforms that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also engages in developing mono-and bispecific anti-tumor antibodies for the treatment of life-threatening diseases; researching, developing, and manufacturing chemical and active pharmaceutical ingredients for human and veterinary medicines; and early identification kidney diseases. Xlife Sciences AG also focuses on functional screening of antibodies by microfluidics-based technologies; and offers Neuromex, a screening instrument for the early-stage detection of neurodegenerative diseases. Xlife Sciences AG was founded in 2019 and is based in Zurich, Switzerland.
Headquarters (address) |
Talacker 35 Zurich 8001 Switzerland |
Phone | 41 44 385 84 60 |
Website | https://www.xlifesciences.ch |
Employees | 17 |
Sector | Healthcare |
Industry | Biotechnology |
Ticker | XLS |
Exchange | Swiss Stock Exchange |
Currency | CHF |
52 week range | 22.50 - 51.40 |
Market Capitalization | 164.21M |
Dividend yield forward | 0.062 % |
Dividend yield forward Switzerland (ID:153, base:169) | 13.52 % |
P/E trailing | 8.77 |
P/E forward | -44.69 |
Price/Sale | 165.83 |
Price/Book | 0.598 |
Beta | 0.554 |
EPS | 3.26 |
EPS Switzerland (ID:153, base:185) | 29.31 |
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Xlife Sciences AG has raised their dividend 0.062 years in a row. This is below the 41125.084400 year average in the 'Biotechnology' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Xlife Sciences AG has raised their dividend 0.062 years in a row. This is below the 41125.084400 year average in the 'Biotechnology' industry